Literature DB >> 11127827

The Hairy and Enhancer of Split homologue-1 (HES-1) mediates the proliferative effect of 17beta-estradiol on breast cancer cell lines.

A Ström1, N Arai, J Leers, J A Gustafsson.   

Abstract

The mechanism behind hormone dependent growth of breast cancer is presently not well understood. We show that the HES-1 protein level in the breast cancer cell lines T47D and MCF-7 is down regulated by 17beta-estradiol treatment. This regulation could be reversed by addition of the anti-estrogens 4OH tamoxifen, raloxifen and Imperial Chemical Industries (ICI) 182,780. In T47D cells with inducible exogenous HES-1 expression, induced expression of HES-1 protein prevented the proliferative effect of 17beta-estradiol and subsequent up regulation of proliferating cell nuclear antigen (PCNA). An inverse correlation between the HES-1 and PCNA protein levels respectively was found in colon cancer cell lines. These findings point to a potential role of HES-1 as a tumor suppressor in epithelial cells, and as a mediator of 17beta-estradiols proliferative effect on breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11127827     DOI: 10.1038/sj.onc.1203990

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  15 in total

1.  A crossroad of microRNAs and immediate early genes (IEGs) encoding oncogenic transcription factors in breast cancer.

Authors:  Aldema Sas-Chen; Roi Avraham; Yosef Yarden
Journal:  J Mammary Gland Biol Neoplasia       Date:  2012-02-12       Impact factor: 2.673

Review 2.  Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy.

Authors:  Jiao Zhang; Yan-Hua Chen; Qun Lu
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

3.  TNFα enhances cancer stem cell-like phenotype via Notch-Hes1 activation in oral squamous cell carcinoma cells.

Authors:  Sung Hee Lee; Hannah S Hong; Zi Xiao Liu; Reuben H Kim; Mo K Kang; No-Hee Park; Ki-Hyuk Shin
Journal:  Biochem Biophys Res Commun       Date:  2012-06-20       Impact factor: 3.575

Review 4.  Hes1: the maestro in neurogenesis.

Authors:  Sivadasan Bindu Dhanesh; Chandramohan Subashini; Jackson James
Journal:  Cell Mol Life Sci       Date:  2016-05-27       Impact factor: 9.261

Review 5.  Role of Notch and its oncogenic signaling crosstalk in breast cancer.

Authors:  Shanchun Guo; Mingli Liu; Ruben R Gonzalez-Perez
Journal:  Biochim Biophys Acta       Date:  2010-12-28

6.  Expression of Notch receptors, ligands, and target genes during development of the mouse mammary gland.

Authors:  Ahmed Raafat; Anita S Goldhar; Malgorzata Klauzinska; Keli Xu; Idean Amirjazil; David McCurdy; Karim Lashin; David Salomon; Barbara K Vonderhaar; Sean Egan; Robert Callahan
Journal:  J Cell Physiol       Date:  2011-07       Impact factor: 6.384

7.  HES1-mediated inhibition of Notch1 signaling by a Gemini vitamin D analog leads to decreased CD44(+)/CD24(-/low) tumor-initiating subpopulation in basal-like breast cancer.

Authors:  Jae Young So; Joseph Wahler; Soumyasri Das Gupta; David M Salerno; Hubert Maehr; Milan Uskokovic; Nanjoo Suh
Journal:  J Steroid Biochem Mol Biol       Date:  2014-12-23       Impact factor: 4.292

8.  Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D.

Authors:  Anders Ström; Johan Hartman; James S Foster; Silke Kietz; Jay Wimalasena; Jan-Ake Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-26       Impact factor: 11.205

9.  The expressions of bHLH gene HES1 and HES5 in advanced ovarian serous adenocarcinomas and their prognostic significance: a retrospective clinical study.

Authors:  Xinyu Wang; Yajuan Fu; Xiaoduan Chen; Jing Ye; Bingjian Lü; Feng Ye; Weiguo Lü; Xing Xie
Journal:  J Cancer Res Clin Oncol       Date:  2009-12-20       Impact factor: 4.553

10.  Hes-6, an inhibitor of Hes-1, is regulated by 17beta-estradiol and promotes breast cancer cell proliferation.

Authors:  Johan Hartman; Eric W-F Lam; Jan-Ake Gustafsson; Anders Ström
Journal:  Breast Cancer Res       Date:  2009-11-05       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.